• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Precision Biosciences Inc (NQ: DTIL )

    9.020 +0.460 (+5.37%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Precision Biosciences Inc

    < Previous 1 2 3 4 5 Next >
    Precision BioSciences to Report Third Quarter Results on November 4, 2024
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences to Present at the Upcoming H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare Conference
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences to Participate in Upcoming August Investor Conferences
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences to Report Second Quarter Results on August 1, 2024
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences Announces its Addition to the Russell Microcap® Index
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver Congress
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences to Participate in Upcoming June Investor Conferences
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences to Report First Quarter Results on May 13, 2024
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
    From Precision BioSciences
    Via Business Wire
    Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
    From Precision BioSciences, Inc.
    Via Business Wire
    Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
    From Precision BioSciences, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.